Saudi Arabia Clinical Trials Market & Regulations Insight 2025 - A US$ 200 Million Market Opportunity
Report Highlights
Saudi Arabia Clinical Trials Market Opportunity: US$ 200 Million
Comprehensive Insight on Clinical Trials Studies in Saudi Arabia: > 400 Studies
Clinical Trials Studies by Indication, Phase & Sponsor
Regulatory Framework & Clinical Trials Guidelines
Insight on Domestic CRO Operating in Saudi Arabia: 15 CRO
Overview on Existing Healthcare Infrastructure & Medical Professionals Like Doctors, Dentist, Nurses
Saudi Arabia is making significant strides in expanding its clinical research sector, aligning with the broader objectives of Vision 2030, which prioritizes scientific advancement and innovation. The Saudi government is actively enhancing research education and investing in clinical trials to improve healthcare outcomes. A key player in this transformation is the Saudi National Institute of Health (NIH), which has launched several initiatives to raise the quality and quantity of research conducted within the country. These efforts include establishing cutting-edge research facilities, fostering an environment where clinical trials can thrive, and setting new benchmarks for excellence.
By strengthening its focus on clinical trials, Saudi Arabia aims to develop medical treatments tailored to its population's specific genetic and health profiles. This is particularly important given the high prevalence of conditions such as diabetes and cardiovascular diseases, which require targeted treatment approaches. Addressing these health challenges through locally relevant clinical research ensures that therapies are better suited to the Saudi population, improving both patient outcomes and the overall healthcare system.
A closer look at the therapeutic areas of focus reveals that oncology, endocrinology, cardiology, and infectious diseases dominate Saudi Arabia's clinical trial landscape. These fields have attracted significant attention due to their widespread impact on public health. Pharmaceutical companies play a crucial role in this ecosystem, serving as the primary sponsors of most clinical trials, particularly multinational studies that require extensive resources and collaboration. Meanwhile, local researchers are actively involved in studies that focus specifically on the Saudi population, addressing region-specific health concerns.
Geographically, the majority of clinical trial sites are concentrated in urban centers, with Riyadh serving as the leading hub for research activities. The Makkah region and the Eastern Province also play significant roles, reflecting a broader trend where research efforts are primarily centered in areas with well-established medical infrastructure and access to specialized expertise. This concentration of research activity enables more efficient coordination of trials and facilitates collaborations between healthcare institutions, regulatory bodies, and industry stakeholders.
As Saudi Arabia's clinical research landscape continues to develop, there has been a noticeable rise in the number of clinical trial applications under review. The Saudi Food and Drug Authority (SFDA) is working diligently to strengthen its regulatory framework, ensuring that all studies meet stringent safety and efficacy standards. This regulatory progress is crucial as the country seeks to attract more international multicenter trials, allowing it to integrate into the global clinical research ecosystem.
The SFDA's efforts include refining approval processes, implementing robust monitoring systems, and ensuring compliance with international best practices. These improvements are particularly vital as Saudi Arabia moves toward more sophisticated trial designs, including precision medicine approaches and innovative drug development strategies.
Additionally, the country is placing greater emphasis on translational research, bridging the gap between laboratory discoveries and real-world clinical applications. By fostering a research-friendly environment and maintaining high regulatory standards, Saudi Arabia is positioning itself as a key player in the global clinical trials landscape, driving advancements that will shape the future of healthcare both regionally and beyond.
Key Topics Covered:
1. Saudi Arabia Clinical Trials Market Outlook
1.1 Current Scenario
1.2 Future Growth Outlook
2. Saudi Arabia Pharmaceutical Market Analysis
2.1 Overview
2.2 Regulatory Framework
2.3 Branded v/s Generic Drugs Availability
3. Saudi Arabia Clinical Trials Overview
3.1 by Phase
3.2 by Sponsors
4. Saudi Arabia Clinical Trials Insight by Company, Indication & Phase
4.1 Phase I
4.2 Phase I/II
4.3 Phase I/IIIB
4.4 Phase II
4.5 Phase II/III
4.6 Phase III
4.7 Phase IV
4.8 Phase BE
5. Saudi Arabia Clinical Trials Regulatory Framework & Guidelines
5.1 Overview
5.2 Drug Safety Monitoring Initiatives
5.3 Regulations For Conducting Clinical Trials on Drugs
5.4 Regulation For Drugs Approval
5.5 Guidelines For Investigational New Drugs (IND)
6. Healthcare Infrastructure & Manpower in Saudi Arabia
7. Saudi Arabia Clinical Trials Market Dynamics
7.1 Drivers & Opportunities
7.2 Challenges & Restraints
8. Clinical Research Organizations Operating in Saudi Arabia
ArabMed CRO
Baahith
Balsam Clinical Research
CLINLIA
ClinServ International
CTI
KAU Med CRO
MCT CRO
Mesned
Monitoring Force Gulf Limited
PDC CRO
Phoenix Clinical Research
RAY CRO
SALA CRO
SGS
For more information about this report visit https://www.researchandmarkets.com/r/lulo4c
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 03/10/2025 08:10 AM/DISC: 03/10/2025 08:10 AM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Dr. Oz on the future of US healthcare: 'There is a new sheriff in town'
Listen and subscribe to Decoding Retirement on Apple Podcasts, Spotify, or wherever you find your favorite podcasts. In an exclusive interview on Yahoo Finance's Decoding Retirement podcast, Dr. Mehmet Oz, the administrator of the Centers for Medicare & Medicaid Services (CMS), discussed the financial and operational challenges facing the US healthcare system. Ultimately responsible for the healthcare of 66 million Medicare beneficiaries, 78 million people enrolled in Medicaid and the Children's Health Insurance Program (CHIP), and millions more in Affordable Care Act health plans, Oz weighed in on issues ranging from new Medicaid work requirements to Medicare Advantage fraud. This embedded content is not available in your region. Medicaid work requirements The Congressional Budget Office (CBO) estimates that the One Big Beautiful Bill Act (OBBBA) could reduce federal Medicaid spending by $793 billion over the next decade and lead to 10.9 million fewer enrollees by 2034. This is partially attributed to the Medicaid work requirements the OBBA will make states enforce for certain adult enrollees by Jan. 1, 2027, which generally involves 80 hours per month of work, community service, education, or work programs. The CBO estimates the requirement will decrease coverage by 5.2 million enrollees by 2034. Concerns about red tape are not hypothetical: In Georgia, where work requirements are already in place, reports show that otherwise eligible workers are losing coverage simply because of paperwork hurdles. However, Oz said that technology and digital solutions could help beneficiaries comply with the rules without losing coverage. 'We've already launched two pilots in Louisiana and Arizona with good results so far,' Oz said. The new digital process, he explained, uses a smartphone app to verify work automatically through payroll providers. "The people running it are the same folks who fixed the passport system in America,' he said. 'Ninety-one percent of people on Medicaid have smartphones. You tap on the smartphone within the app where you're working. Let's say you're an Uber driver, it knows that ADP does your payroll, and so it asks you permission, 'Can I contact ... ADP and ask them about your hours?' You say yes, and boom, ... the entire process is less than seven minutes." Oz, however, stopped short of addressing some key questions, such as how many people might lose coverage under the current system or whether administrative barriers will unfairly affect millions before the new technology is fully in place. Medicare Advantage and 'upcoding' Oz weighed in on the controversy swirling around Medicare Part C, better known as Medicare Advantage. About 33 million people are enrolled in these private plans, offered by companies such as UnitedHealth Group (UNH) and CVS Health (CVS). Medicare Advantage allows enrollees to receive Part A (hospital), Part B (medical), and, when bundled, Part D (prescription drug) coverage in one plan. The program has been under a harsh spotlight. Earlier this month, UnitedHealth confirmed it is under federal investigation. And a Wall Street Journal story detailed how some Medicare Advantage providers allegedly exploited the system through questionable or outright fraudulent billing practices. 'The whole point of launching Medicare Advantage was to give seniors options," Oz said. "But in the middle of all this, if it turns out that Medicare Advantage is costing us a lot more than fee-for-service, you're violating the whole premise.' The big problem is 'upcoding," the practice of inflating the severity of patients' conditions to trigger higher government payments. 'In Medicare Advantage, I do think that there's been an ability for the private companies to game the coding system,' Oz said. 'Instead of just saying, 'I got what I got, I'm going to take care of them and be honest about how sick they are,' they expertly devised tactics to upcode to pretend the patients were sicker than they really were. That got them more money.' Oz said CMS is now taking aggressive steps to recover funds and send a message: 'We have a process called RADV that allows us to go back to the late teens and, for the first time, audit Medicare Advantage companies,' he said. 'Based on what we find, we're going to pull money back from them. We expect it will be billions and billions of dollars. But more importantly, we're sending a message to the industry: Listen, I want you to succeed. I want you to thrive, but not at the expense of the American taxpayer.' Concern about Medicare's financial future According to the 2025 OASDI Trustees Report, Medicare Part B premiums are expected to rise 11.6% in 2026 to $206.50 a month — the steepest single-year increase in nearly a decade. At the same time, the Medicare Hospital Insurance Trust Fund, which finances Part A, is projected to run dry in 2033. If Congress doesn't intervene, that insolvency would trigger an automatic 11% cut in covered hospital services. Oz called the looming Part B increase a 'major concern,' citing the surge in prescription drug prices as the primary culprit. 'But there are other things,' Oz said, 'that are in Part B as well that we believe we have control over and we could get to be more efficient.' Rather than promising immediate regulatory fixes, Oz said his agency should work directly with industry. 'A lot of this is hearing the stakeholders and then pushing back on what you've heard and then letting them actually come up with some ideas themselves,' he said. 'We've gone back to all of them and said, we need better answers. What you're doing now is making you a lot of money, and you can do that for another year or two — and then the bottom's going to fall out.' 'The … Trustees Report predicts that [Part A] is bankrupt in 2033,' Oz added. 'That's three years shorter than we thought a month ago. And in their worst-case scenario, it goes bankrupt in [2029].' For context, Medicare Part A is primarily funded through a dedicated payroll tax under the Federal Insurance Contributions Act, or FICA. The total Medicare tax rate is 2.9% of wages — typically split evenly between employee and employer. That means 1.45% is withheld from your paycheck, and your employer contributes the other 1.45% on your behalf. Navigating Medicare open enrollment As Medicare's annual open enrollment period approaches — beginning Oct. 15 for 2026 coverage — millions of beneficiaries will face one of the biggest financial decisions of the year: whether to stick with their current plan or make a change. Most Medicare beneficiaries never switch plans, even though premiums, provider networks, and drug formularies can change from year to year. So how might retirees navigate this? 'We have to give people information,' Oz said. 'At the same point, I don't want people to panic and jump to changes." His advice is simple: Do your homework, but don't feel pressured to change plans unless you have a clear reason. One big resource is 1-800-MEDICARE. 'It's easy to remember, and it's got a ton of information,' he said. 'Especially during open enrollment, I strongly urge you to do a little work.' Hospice scams Healthcare scams are on the rise — and Medicare beneficiaries are among the top targets. The CMS recently sounded the alarm in a blog post and video featuring Oz, warning older Americans to be on guard for this disturbing trend. 'Beware of scammers, sometimes posing as salespeople, offering 'free' services or gifts,' the CMS blog warned. 'They may be trying to trick you into signing up for hospice care without your knowledge.' 'This is a reprehensible activity,' Oz said. 'It's run by criminal syndicates — not small-time operators. They take advantage of people at their most vulnerable time.' Hospice fraud is insidious because it targets people making some of the most difficult decisions of their lives. Oz said, 'We are hearing horror stories about people who thought they were entering legitimate hospice and there's nothing there for them. And even worse — because you're not really sick — people are on these hospice programs for years. We're going after them in a big way.' 'There is a new sheriff in town' Oz promised a tougher stance against healthcare fraud, both foreign and domestic. 'We already have actions in several states,' he said. 'The Department of Justice is pursuing a lot of these leads. We will leave no stone unturned. There is a new sheriff in town. I promise you, if you're cheating the American people, we will come after you. And if you're doing it to hurt folks who are most vulnerable — we'll be doubly vigilant.' Beyond enforcement, Oz emphasized that better technology and patient identification are key to preventing fraud before it happens. 'You're talking about an agency with a $1.7 trillion budget,' Oz said. 'One policy memo can affect [tens of millions of Americans.] We have to get it right.' One key will be distilling the complexity of the system into actionable information for both the public and his team. 'The goal is the same as it was" on his TV show, Oz said. "Explain it so people understand it and can act on it,' he said. 'If we simplify the rules, give people clear guidance, and enforce the protections already in place, we can change outcomes for millions of Americans." Got questions about retirement? Email Robert Powell at yfpodcast@ and we'll do our best to answer it in a future episode of Decoding Retirement. Each Tuesday, retirement expert and financial educator Robert Powell gives you the tools to plan for your future on Decoding Retirement. You can find more episodes on our video hub or watch on your preferred streaming service. Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Option Care Health, Inc. (OPCH): A Bull Case Theory
We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
17 hours ago
- Bloomberg
Canada Wildfires Worsen Air Quality Across Midwest, Northeast US
Smoke and grit from hundreds of forest fires have spread across large parts of Canada and the northern US, sending air quality across the Midwest and northeast US and Toronto to unhealthy levels. Air quality deteriorated to moderate in Chicago early Sunday with some areas unhealthy for sensitive groups, and to unhealthy in Milwaukee and downtown Toronto, Canada's largest city, according to Alerts were raised across Canada from the Northwest Territories to Quebec, as well as in 10 US states from Minnesota to Maine, including Upstate and western New York.
